Karo Pharma divests Hydrokortison Trimb to Evolan Pharma
As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and all intellectual property rights and assets relating thereto, including necessary licenses and permits as well as existing stock, to an external buyer approved by the Swedish Competition Authority (the “Competition Authority”). This was part of the closing conditions for the acquisition of Trimb Holding AB (“Trimb””) in September 2019. During the financial year 2018, the total sales of Hydrokortison Trimb amounted to SEK 19.8 million. Karo